Cetera Investment Advisers Sells 59,212 Shares of Haleon plc (NYSE:HLN)

Cetera Investment Advisers trimmed its stake in shares of Haleon plc (NYSE:HLN) by 25.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 174,576 shares of the company’s stock after selling 59,212 shares during the quarter. Cetera Investment Advisers’ holdings in Haleon were worth $1,442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Clearbridge Investments LLC grew its stake in Haleon by 44.6% during the first quarter. Clearbridge Investments LLC now owns 38,446,978 shares of the company’s stock worth $326,415,000 after purchasing an additional 11,865,076 shares during the period. Wellington Management Group LLP boosted its position in shares of Haleon by 164.6% during the fourth quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock valued at $111,454,000 after buying an additional 8,423,475 shares during the last quarter. Martin Investment Management LLC lifted its holdings in Haleon by 12,018.4% during the first quarter. Martin Investment Management LLC now owns 4,463,205 shares of the company’s stock worth $37,893,000 after acquiring an additional 4,426,375 shares during the period. Sculptor Capital LP lifted its holdings in Haleon by 67.8% during the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after acquiring an additional 3,592,000 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in Haleon by 95.5% during the second quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock worth $16,143,000 after acquiring an additional 954,622 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Haleon Price Performance

Shares of NYSE HLN opened at $10.02 on Wednesday. The stock has a market cap of $45.75 billion, a PE ratio of 33.40, a price-to-earnings-growth ratio of 2.93 and a beta of 0.26. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a fifty day moving average of $10.19 and a 200-day moving average of $9.11.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $3.50 billion during the quarter, compared to analysts’ expectations of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same quarter last year, the firm posted $0.08 earnings per share. Equities research analysts anticipate that Haleon plc will post 0.47 earnings per share for the current year.

Haleon Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were given a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s dividend payout ratio (DPR) is presently 33.33%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. UBS Group upgraded Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research note on Friday, September 20th. The Goldman Sachs Group lowered Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Finally, Berenberg Bank began coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Haleon currently has a consensus rating of “Buy” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.